Brind.
  1. Kazia Therapeutics Limited is evaluating Paxalisib in combination regimens for advanced triple negative breast cancer through a Phase 1b trial.

Kazia Therapeutics Limited announced clinical trial updates from Sydney on May 26, 2026.

2 reports, 2 independent Updated May 26
Gone quiet
Reports
2
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Kazia Therapeutics Limited announced clinical trial updates from Sydney on May 26, 2026.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Kazia Therapeutics' clinical trial utilizes Merck's Keytruda.Sub-event
  2. Clinical trial updates announced from Sydney.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped